, will1 ctll;~~lol, c~~~l~c d ( l c d ill pilrolfi!~ and scctio~lcd. Tlley were stailled wit11 Llle irrdirccl nlctllod using enzyme labelc(l alltiho(ly. 'l'llc ~)osilive stailll~lg was observed ill thc cy1ol)lasln of Ilcl)alocytes, I<ul~ffcr cells arid c~~~l o t l~c l i a l cells, suggestirrg tllat tllesc type cells contain xanthine (lelrydrogcnase. After isolation of hcpatocytes most of xantlline dcl~ytlrogcnnsr was recovered in 100,000xg supernata~ll fraction from Ilomogerralc of lrepatocytes and Llie specific activity of enzyme was similar Lo that ill 100,000xg superrratallt fraction fl-om I~omogcr~ale o l liver. who was begun on red cell wnsfusions and immunoglobulin replacement therapy at 6 months of age. Despite long term survival. she remained severely lymphopenic and immune deficient. After starting PEG-ADA therapy at age 10 years her lymphocytes increased and became responsive to mitogens, and she developed in vivo B cell function. Just prior to starting PEG-ADA, unfractionated nucleated cells from her bone marrow were found to have 4 % of normal ADA activity, b u~ 1L-2 dependent T cells cultured from this marrow sample had near normal activity (>I000 nmol/h/mg protein). This observation was repeated with blood and marrow derived mononuclear cells and IL2-dependent T cells and T cell clones on 6 other occasions. HLA typing indicated the ADA+ T cells were the patient's own cells. T cell ADA had normal heat stability. Km, pI and was inhibited >99% by EHNA. In connast to her T cells, 12 EBV transformed B cell clones from the patient had ~0 . 3 % of normal ADA activity. ADA+ T cells had n o m d T cell surf~ce antigens and responsed in vitro to IL-2, mitogens, antigen and allogsneic cells. Imponant questions raised by these findings concern the molrcullrr basis for the T cell ADA activity and the reason that these cells failed to proliferate and function more effecuvely in this patient in vivo. Acquisition of ADA activity by T lymphocyte precursor cells may not be sufficient to restore immune function in some ADA deficient patients. This possibility should be considered in view of proposals to treat ADA deficiency by somatic cell gcne replacement. P a l e l l a . University of Michigan, Department of I n t e r n a l Medicine, Ann Arbor, Michigan Human adenine phosphoribosyltransferase (APRT) deficiency i s a r e l a t i v e l y common genetic disorder caused by a defective APRT gene, r e s u l t i n g i n 2,8-dihydroxyadenine u r o l i t h i a s i s . The k i n e t i c p r o p e r t i e s of APRT from APRT-deficient Japanese s u b j e c t s showed s i m i l a r abnormalities suggesting a d i s t i n c t "Japanese-type* mutation.
HUMAN ADENINE PHOSPHORIBOSYLTRANSFERASE (APRT)
Nucleotide sequence a n a l y s i s of APRT genomic DNA from WR2, a Japanese-type homozygote, i d e n t i f i e d a T t o C s u b s t i t u t i o n i n exon 5 on both a l l e l e s (~e t l~~+~h r ) .
RNase mapping a n a l y s i s revealed t h a t s i x other Japanese-type homozygotes c a r r i e d the same mutation on a t l e a s t one a l l e l e .
After amplifying the region of t h e APRT genomic DNA t h a t contains the Japanese-type mutation by the polymerase chain r e a c t i o n (PCR), dot-blot a n a l y s i s was performed using normal and mutated a l l e l e s p e c i f i c oligonucleotide (ASO) probes.
This method demonstrated t h a t a l l seven Japanese-type homozygotes c a r r i e d the same mutation on both a l l e l e s .
The dot-blots c l e a r l y d i s t i n g u i s h normal. Japanese-type heterozygotes and Japanese-type homozygotes. PCR of genomic sequences and AS0 hybridization i s a u s e f u l t o o l f o r d e t e c t i o n of common mutations i n defined populations. such a s "Japanese-type" APRT deficiency. P388 m u r i n e l e~k e m i f~c e l l s w e r e i n c u b e t e d w i i h tyg d i f f e r e n t t y p e s o f C -l a b e l e d B H A C , ( c y t o s i n e -2 -C) BHAC a n d ( a c y l -1 -. *C)BHAC, a n d DNA w a s e x t r a c t e d w i t h p h e n o l . And t h e n t h e p h e n o l e x t r a c t e d DNA was h y d r o l y z e d b y n u c l e a s e P 1 a n d a n a l y z e d w i t h h i g hp e r f o r m a n c e l i q u
l d c h r o m a t o g r a p h y ( H P L C ) . T h e r a d i o a ct i v i i y o f DNA, f r o m t h e c e l l s i n c u b a t e d w i i h ( c y t o s i n e -2-C)BHAC,was d e t e c t e d a s Ara-CMP. B u t t h e r a d l o a c -I i v i t y o f DNA, f r o m t h e c e l l s i n c u b a t e d w i t h ( a c y l -1 -C)BHAC,was a l m o s t n o t d e t e c t e d . On t h e o t h e r h a n d , t h e m a i n r a d i o a c t i v i t y o f a c i d s o l u b l e f r a c t i o n w a s d e t e r m i n e d a s Ara-CTP. On t h e b a s i s o f o u r r e s u l p , BrlAC i s n o t p h o s p h o r y l a t e d d i r e c t l y t o p r o d u c e N -
b e h e n o l y -a r a --C T P , b u t m a i n l y o n c e c o n v e r t e d t o Ara-C a n d i t s u b s e q u e n t l y p r o d u c e s A r a -C T P , t h e a c t i v e m e t a b o l i t e o f t h e d r u g , a n d r h e n i n c o r p o r a t e d i n t o DNA. The aim of t h i s study was t o examine whether pyrazinamide and a l l o p u r i n o l were metabolized i n t h r e e xanthinuric p a t i e n t s of two f a m i l i e s of hereditary xanthinuria lacking xanthine oxidase because we were i n t e r e s t e d i n whether both pyrazinamide and a l l o p u r i n o l were oxidized only by xanthine oxidase o r by other kinds of oxidase. A xanthinuric p a t i e n t , t h e propositus of a family of xanthinuria could n e i t h e r metabolize pyrazinamide i n t o 5-hydroxypyrazinamide nor a l l o p u r i n o l i n t o oxypurinol. Two xanthinuric p a t i e n t s , the propositus of the o t h e r family of xanthinuria and h i s e l d e r brother could metabolize both pyrazinamide i n t o 5-hydroxypyrazinamide and a l l o p u r i n o l i n t o oxypurinol. These r e s u l t s suggests t h a t xanthinuria c o n s i s t s of a t l e a s t two subgroups; one does not possess pyrazinamidea l l o p u r i n o l oxidizing enzyme(s) other than xanthine oxidase o r possesses a v a r i a n t form of xanthine oxidase which can n e i t h e r metabolize oxypurines nor pyrazinamide o r a l l o p u r i n o l , and t h e other possesses p y r a z i n a m i d e -a l l o p u r i n o l oxidizing enzyme(s) or possesses the o t h e r v a r i a n t form of xanthine oxidase which can not metabolize oxypurines but can do both pyrazinamide and a l l o p u r i n o l . an "enhryrmic" transcript (3.4 W ) and peptide: postnatal s k e l e t a l mujcle c o n t a i n s an "adult" transcript (2.5 Kb) and peptide. ' Ihe l a t t e r are restricted to striated nuscle. E x d u c t i o n of the a d u l t p e p t i d e is c o n t r o l l e d by t r a n s c r i p t switching, increase in transcript abudxce during mcjcledevelooment ard u s s i b l v e f f i c i e n c v o f t r a n s l a t i o n . 3) Fcur p a t i e n t w i t h A e r i t e d -d e f i c i e n c y -o f AMP-D have been evaluated w i t h these probes. AlthMlgh b m m o r e a d i v e p e p t i d e is absent f m their s k e l e t a l -le, the abunjanoe o f t h e 2.5 W nwcles p e c i f i c transcript is normal. We conclude f m these s t u d i e s that 1). AMP-D expression is c o n t r o l l e d a t r m l t i p l e steps during m y c q t e d e v e l o p w r t 2) I n h e r i t e d d e f i c i e n c y o f the m l es p e c i f i c isofonn cannot be explained by a d e f e c t i n t r a n s c r i p t switching o r rate o f t r a n s c r i p t i o n ! suggesting a d e f e c t i n t r a n s l a t i o n o r a s-le base substitution.
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